Ingenia wins KOSDAQ nod, advances MSD-partnered eye drug to global phase 3 Boston-founded biotech aims IPO as MSDs macular ...
MSD's TROP2-targeting antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), licensed from China's Kelun-Biotech, has improved survival in a late-stage endometrial cancer trial. The positive ...
Pharmaceutical Technology on MSN
MSD concludes Terns acquisition to expand CML pipeline
The FDA granted breakthrough therapy designation to TERN-701 for adults with Philadelphia chromosome-positive CML without the ...
Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race Kelun partnerships sac-TMT shows survival ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results